AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
58 hedge funds and large institutions have $72.3M invested in AVEO Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
98% more call options, than puts
Call options by funds: $2.75M | Put options by funds: $1.39M
12% more funds holding
Funds holding: 52 → 58 (+6)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
22% less capital invested
Capital invested by funds: $92.7M → $72.3M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.54M |
| 2 |
Millennium Management
New York
|
+$1.23M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$811K |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
+$620K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$400K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$2.74M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.19M |
| 3 |
Morgan Stanley
New York
|
-$247K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$218K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$207K |
AVEO Hedge Fund Activity: Q4 2021 in Review
58 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2021, worth a combined $72.3M — down 22% from $92.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AVEO positions and 6 closed out — a net gain of 6 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $3.54M. The largest seller was J. Goldman & Co, cutting an estimated $2.74M.
- 58 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2021, up from 52 in Q3 2021.
- Funds reported $72.3M of AVEO Pharmaceuticals, Inc. stock for Q4 2021, down 22% quarter-over-quarter.
- 12 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2021 and 6 closed out, a net change of +6 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2021 was AIGH Capital Management, an estimated $3.54M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2021 was J. Goldman & Co, an estimated $2.74M sold.
Based on aggregated 13F filings for Q4 2021.